|
|
Article: ChemGenex Pharmaceuticals Receives European Patent Allowance for Cancer Drug, Quinamed.
- Article from:
- Business Wire
- Article date:
- February 17, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MELBOURNE, Australia & MENLO PARK, Calif. -- Covers Use of Quinamed(R) (amonafide dihydrochloride) to Boost the Effect of Common Cancer Therapies
ChemGenex today announced that it received a Notice of Allowance from the European Patent Office (EPO) for its patent application entitled "Compositions Containing Naphthalimide and an Antiproliferative Agent." This patent will cover compositions and methods of use of the company's investigational agent, amonafide (Quinamed(R)), to improve or "chemopotentiate" the anti-cancer effects of common chemotherapeutics, including cisplatin, paclitaxel, vinblastine and camptothecin.
Quinamed(R) is currently undergoing ...